Necrosulfonamide |
Katalog-Nr.GC10150 |
Necrosulfonamid (NSA) ist ein spezifischer Inhibitor von MLKL (Mixed Lineage Kinase Domain-ähnliches Protein)[1].
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1360614-48-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
BMDMs |
Preparation Method |
IL-1β and LDH levels in the cell supernantant of BMDMs from WT (C57BL/6), Gsdmd-/- and Caspase-1-/- mice primed for 2.5 hr with LPS (50 ng/ml), with necrosulfonamide (NSA) (10 µM) added in the last 30 min of priming, then treated with MSU crystals (300 µg/ml, 6 hr) or nigericin (10 µM, 1 hr). |
Reaction Conditions |
10 µM; 30 min |
Applications |
The treatment of LPS primed BMDMs with similar concentrations of NSA, (10 µM) efficiently inhibited MSU crystal-induced IL-1β release in a dose dependent manner. |
Animal experiment [2]: | |
Animal models |
Seventy male 8-week-old specific pathogen-free (SPF)-grade C57BL/6J mice weighing 20-25 g |
Preparation Method |
An ALF (Acute liver failure) model was established by lipopolysaccharide/D-galactosamine challenge in C57BL/6J mice. Necrosulfonamide 20 mg/kg was administered by intraperitoneal injection 30 m before the establishment of the animal model. |
Dosage form |
20 mg/kg; i.p. |
Applications |
Pyroptosis was activated in ALF model mice. Mice treated with GSDMD inhibitor Necrosulfonamide developed less severe liver failure. Necrosulfonamide reduced the expression of GSDMD, NLRP3, cleaved caspase-1, cleaved caspase-11, and secretion of interleukin-1 beta in ALF mice model. |
References: [1] Rashidi M, et al. The Pyroptotic Cell Death Effector Gasdermin D Is Activated by Gout-Associated Uric Acid Crystals but Is Dispensable for Cell Death and IL-1β Release. J Immunol. 2019 Aug 1;203(3):736-748. |
Necrosulfonamid (NSA) ist ein spezifischer Inhibitor von MLKL (Mixed Lineage Kinase Domain-ähnliches Protein)[1]. Necrosulfonamid, ein Inhibitor von GSDMD, könnte die durch PPVI induzierte Aktivierung des NLRP3-Inflammasoms hemmen[2].
Im In-vitro-Wirksamkeitstest wurde gezeigt, dass die IC50-Werte für Necrosulfonamid in zellbasierten Tests zur Nekroptose (NEC), Apoptose (APOP) oder Toxizität (TOX) in Jurkat- und U937-Zellen 1399 nM, 6197 nM, 454 nM bzw. >100.000 nM und 14694 nM betrugen[3]. In vitro hemmte eine Behandlung mit 10 µM oder 20 µM Necrosulfonamid die GSDMD-vermittelte Freisetzung von IL-1β nach Inflammasom-Stimulation vollständig, was selbst noch nach 60 Minuten Stimulation bei Zellen, die mit LPS und Nigericin stimuliert wurden, zu einer Unterdrückung von IL-1β führte[4].
In vivo wurden männliche erwachsene C57BL/6-Mäuse zweimal täglich intraperitoneal mit 5 mg/kg Necrosulfonamid verabreicht, was signifikant die Hämatomgröße reduzierte, entzündliche Zellen und Zytokine unterdrückte und die Blut-Hirn-Schranke im Vergleich zu Kontrollen schützte[1]. In vivo wurden Ratten mit Necrosulfonamid (10 mg/kg) injiziert, wodurch die NOD-ähnlichen Rezeptor 3 (NLRP3)-, GSDMD-N-, phosphorylierten MLKL- und phosphorylierten RIP3-Level im Herzmuskelgewebe sowie entsprechende Reduktionen der Entzündungszytokin-Level reduziert wurden[5]. In vivo verbesserte eine intraperitoneale Injektion von 1, 5 oder 10 mg/kg Necrosulfonamid bei Mäusen die motorische Funktion und das Rückenmarksödem bei SCI-Mäusen mit einem therapeutischen Fenster[6]. In vivo wurde Ratten durch intraperitoneale Verabreichung von 0,5 mg/Körpergewicht Necrosulfonamid geschützt vor Lungen-IRI durch Hemmung der Nekroptose[7]. Mäuse wurden mit NSA behandelt (0,5 mg/kg/Tag für drei Tage und dann jeden zweiten Tag i.p. injiziert), was Defekte in der motorischen Leistungsfähigkeit wiederherstellte sowie TH+-Faserdefizite und TH+-Zellverlust in einem Mausmodell von PD[8]. In vivo wurden Ratten intraperitoneal mit 1,65 mg/kg/Tag Necrosulfonamid für sechs Wochen behandelt und zeigten eine deutliche Verbesserung der durch AlCl3 verursachten räumlichen Lern- und Gedächtnisdefizite, wie durch verbesserte Leistung in Morris-Wasser- und Y-Mazes gezeigt wurde[9].
References:
[1] Zhang X, et al. Necrosulfonamide Alleviates Acute Brain Injury of Intracerebral Hemorrhage via Inhibiting Inflammation and Necroptosis. Front Mol Neurosci. 2022 Jun 2;15:916249.
[2] Teng JF, et al. Polyphyllin VI Induces Caspase-1-Mediated Pyroptosis via the Induction of ROS/NF-κB/NLRP3/GSDMD Signal Axis in Non-Small Cell Lung Cancer. Cancers (Basel). 2020 Jan 13;12(1):193.
[3] RÜbbelke M, et al. Locking mixed-lineage kinase domain-like protein in its auto-inhibited state prevents necroptosis. Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33272-33281.
[4] Rathkey JK, et al. Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci Immunol. 2018 Aug 24;3(26):eaat2738.
[5] He F, et al. Necrosulfonamide improves post-resuscitation myocardial dysfunction via inhibiting pyroptosis and necroptosis in a rat model of cardiac arrest. Eur J Pharmacol. 2022 Jul 5;926:175037.
[6] Jiao J, et al. Necrosulfonamide Ameliorates Neurological Impairment in Spinal Cord Injury by Improving Antioxidative Capacity. Front Pharmacol. 2020 Jan 9;10:1538.
[7] Ueda S, et al. Protective effect of necrosulfonamide on rat pulmonary ischemia-reperfusion injury via inhibition of necroptosis. J Thorac Cardiovasc Surg. 2022 Feb;163(2):e113-e122.
[8] Leem YH, et al. Necrosulfonamide exerts neuroprotective effect by inhibiting necroptosis, neuroinflammation, and α-synuclein oligomerization in a subacute MPTP mouse model of Parkinson's disease. Sci Rep. 2023 May 31;13(1):8783.
[9] Motawi TMK, et al. Ameliorative Effect of Necrosulfonamide in a Rat Model of Alzheimer's Disease: Targeting Mixed Lineage Kinase Domain-like Protein-Mediated Necroptosis. ACS Chem Neurosci. 2020 Oct 21;11(20):3386-3397.
Cas No. | 1360614-48-7 | SDF | |
Chemical Name | (E)-N-[4-[[(3-Methoxy-2-pyrazinyl)amino]sulfonyl]phenyl]-3-(5-nitro-2-thienyl)-2-propenamide | ||
Canonical SMILES | COC1=NC=CN=C1NS(=O)(=O)C2=CC=C(C=C2)NC(=O)C=CC3=CC=C(S3)[N+](=O)[O-] | ||
Formula | C18H15N5O6S2 | M.Wt | 461.47 |
Löslichkeit | ≥ 46.1mg/mL in DMSO | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.167 mL | 10.8349 mL | 21.6699 mL |
5 mM | 0.4334 mL | 2.167 mL | 4.334 mL |
10 mM | 0.2167 mL | 1.0835 mL | 2.167 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 23 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *